Leukemia

概述 癌症中心临床科学部的历史植根于癌症中心的早期。它始于丹娜-法伯癌症研究所（DFCI）和波士顿儿童医院（CHB）的合作伙伴关系，该医院成立于20世纪40年代末。DF/HCC联盟的形成导致了一个新的科学环境的发展，该环境促进了临床研究者之间以及与基础和人口同事之间的高度机构间合作。它还提供了宝贵的机会，以更大的病人基础，使有前途的临床试验可以在合理的时间内进行。其结果是通过致力于转化研究并得到单一临床组织结构的支持，形成了一个丰富而有凝聚力的科学界。 组织 促进临床研究的基本组织单位仍然是临床项目。临床科学部包括十个以疾病为重点的项目（例如：前列腺癌）和一个支持转化药理学和早期试验（TPETT）。皮肤肿瘤和黑色素瘤是该应用中的新临床项目。它有着卓越的翻译发现记录，强大的多机构 领导力，创新试验的良好记录，更新的SPORE和活跃的会员。

OVERVIEW The history of the Cancer Center's Clinical Science Division is rooted in the eariiest years of the Cancer Center. It began with the partnership of Dana-Farber Cancer Institute (DFCI) and Children's Hospital Boston (CHB), which was established in the late 1940s. The fomiation of the DF/HCC consortium has resulted in the development of a new scientific environment that fosters a high degree of inter-institutional collaboration among clinical investigators and with basic and population colleagues. It also has provided invaluable access to a far greater patient base so that promising clinical trials can be conducted in a reasonable timeframe. The result has been an enriched and cohesive scientific community unified through a commitment to translational research and supported by a single clinical tiials structure. Organization The basic organizing unit for stimulating clinical research remains the Clinical Programs. The Clinical Science Division includes ten programs that are disease-focused (e.g.. Prostate Cancer) and one that supports translational pharmacology and early phase trials (TPETT). Cutaneous Oncology and Melanoma is a new Clinical Program in this application. It has had an excellent record of translational discovery, strong multiinstitutional leadership, a favorable record of innovative trials, a renewed SPORE and active membership.